Servier was founded in 1954 when Jacques Servier created a pharmaceutical company in Orléans with a vision to serve patient health. What started as a single entity has evolved into a global independent pharmaceutical group governed by a unique non-profit foundation, a structure that enables the company to maintain a long-term vision free from investor pressure. This distinctive governance model allows Servier to reinvest all profits into a single priority: therapeutic progress to serve patient needs worldwide. Today, the company operates in more than 130 countries with over 21,900 employees representing 50+ nationalities, treating approximately 100 million patients daily with Servier Group medicines.
The company has strategically transformed from its origins as a global leader in cardiometabolism to become an oncology powerhouse, dedicating 70% of its R&D budget to oncology while maintaining its strong cardiovascular franchise. Servier invests close to 20% of its brand-name medicine revenue in research and development, focusing on difficult-to-treat cancers, rare neurological disorders, and cardiovascular diseases. This commitment is evidenced by its growing portfolio of first-in-class and best-in-class medicines, including groundbreaking treatments like TIBSOVO and VORANIGO. Servier operates six research centers and 19 International Centers for Therapeutic Research, embodying values of daring to innovate, caring deeply, committing to success, and growing through shared efforts as it works toward its 2030 ambition to impact society by creating benefit for patients and making the world more sustainable.